Clinical outcomes were better when daratumumab was added to a regimen of patients with relapsed/refractory multiple myeloma who received prior therapy. Read More ›

Pharmacokinetic analysis of daratumumab as part of combination regimens identified no clinical or demographic characteristics that altered exposure and activity of the monoclonal antibody. The findings support the body-weight–based dosing of 16 mg/kg. Read More ›

Data from a “real-world” historical cohort of heavily pretreated patients in the Czech Republic confirmed the benefits shown in clinical trials of single-agent daratumumab compared with treatment by physician’s choice. Read More ›

As out-of-pocket costs continue to rise, patients and healthcare stakeholders are increasingly concerned about the relative value of different treatment options. This claims-based analysis assesses trends in novel therapy use, total healthcare costs, and survival outcomes among newly diagnosed multiple myeloma patients in the United States since 2000. Read More ›

Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.

Read More ›

Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.

Read More ›

By prior treatment exposure, all subgroups in the CASTOR trial benefited from the addition of daratumumab to bortezomib/dexamethasone, including patients refractory to lenalidomide at last treatment.

Read More ›